Mandate

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.

The share issue was directed to a number of international and Swedish institutional investors on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Dain Hård Nevonen, Lorin Arabi and Karin Karsten.

Related

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026

Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms

Vinge has advised Mirova, a subsidiary of Natixis Investment Managers focusing on sustainable investments, in connection with the acquisition of the three Swedish onshore wind farms Boarp, Dållebo and Fågelås.
February 10, 2026

Vinge has advised Bridgepoint in its acquisition together with Polaris of a majority stake in PDSVISION, a global leader in digital engineering

Headquartered in Stockholm, PDSVISION operates across North America, Europe and Asia. The company delivers integrated software and services that support digital transformation in product development and manufacturing, helping customers improve productivity and accelerate the journey from concept to production. The company has built a subscription-led business with ~SEK 1.7 billion in revenues, characterised by longstanding customer relationships and strong organic growth.
February 10, 2026